Clinical outcomes with immune checkpoint inhibitors in patients with FGFR2/3, MTAP or ERBB2 genomic alterations in advanced urothelial carcinoma von Talukder, Rafee, MD, Dimitra Rafailia Bakaloudi, Makrakis, Dimitrios, Diamantopoulos, Leonidas N., Enright, Thomas, Leary, Jacob, Raychaudhuri, Ruben, Tripathi, Nishita, Agarwal, Neeraj, Jindal, Tanya, Brown, Jason R., Zakharia, Yousef, Rey-Cárdenas, Macarena, Castellano, Daniel, Nguyen, Charles B., Alva, Ajjai, Zakopoulou, Roubini, Bamias, Aristotelis, Barrera, Rafael Morales, Marmorejo, David, Drakaki, Alexandra, Pinato, David J., Korolewicz, James, Buznego, Lucia Alonso, Duran, Ignacio, Carballeira, Clara Castro, McKay, Rana R., Stewart, Tyler F., Gupta, Shilpa, Barata, Pedro, Yu, Evan Y., Koshkin, Vadim S., MD, Ali Raza Khaki, Grivas, Petros

Volltext